Abstract
Fat accumulates within the body of a person who is overweight or obese until many small physiological changes accumulate to a tipping point where adipose tissue becomes “sick.” Adisopathy or “sick fat” leads to a host of other obesity-related diseases. In this chapter the development of adisopathy is discussed in detail with an emphasis on insulin resistance and the role of mitochondria, hormones, inflammatory markers and leptin. This chapter describes the mechanisms of disease for prediabetes and type 2 diabetes and explores the concept of metabolic syndrome. It also explains the pathophysiology of obesity as it relates to non-alcoholic fatty liver disease (NAFLD). The chapter ends with specific discussions about the relationships between obesity and other obesity-related diseases, including hypertension, dyslipidemia, atherosclerosis, coronary heart disease and stroke.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diab Care. 2009;32(12):2297–9.
Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:92–103.
Messer JI, Jackman MR, Willis WT. Pyruvate and citric acid cycle carbon requirements in isolated skeletal muscle mitochondria. Am J Physiol Cell Physiol. 2004;286(3):C565–72.
Hoppeler H, Fluck M. Plasticity of skeletal muscle mitochondria: structure and function. Med Sci Sports Exerc. 2003;35:95–104.
Chomentowski P, Coen PM, Radikova A, Goodpaster BH, Toledo FG. Skeletal muscle mitochondria in insulin resistance: differences in intermyofibrillar versus subsarcolemmal subpopulations and relationship to metabolic flexibility. J Clin Endocrinol Metab. 2011;96:493–503.
Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89–94.
Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011;95(5):875–92.
Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 1998;83:2773–6.
Reaven GM. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diabetes Vasc Dis Res. 2005;2:105–12.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320–5.
Qu H, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The definition of insulin resistance using HOMA-IR for American of Mexican descent using machine learning. PLoS ONE. 2011;6(6):e21041.
Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, DeFrancisco A, Quintela AG. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.
Rasmussen-Torvik LJ, Pankow JS, Jacobs DR, Steffen LM, Moran AM, Steinberger J, Sinaiko AR. Heritability and genetic correlations of insulin sensitivity measured by the euglycemic clamp. Diabet Med. 2007;24(11):1286–9.
Staten MA, Stern MP, Miller WG, Steffes MW. Campbell SE for the insulin standardization workgroup. Diabetes Care. 2010;33(1):205–6.
Johnson JL, Duick DS, Chui MA, Aldasouqi SA. Identifying prediabetes using fasting insulin levels. Endocr Pract. 2010;16(1):47–52.
Ter Horst KW, Gilijamse PW, Koopman KE, de Weijer BA, Brands M, Kootte RS, et al. Insulin resistance in obesity can be reliably identified from fasting plasma insulin. Int J Obes. 2015. doi:10.1038/ijo.2015.125.
Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette smoking on insulin resistance risk. Ann Cardiol Angeiol (Paris). 2015. doi:10.1016/j.ancard.2014.12.001.
Scherag A, Jarick I, Grothe J, Biebermann H, Scherag S, Volckmar AL, et al. Investigation of a genome wide association signal for obesity: synthetic association and haplotype analysis at the melanocortin 4 receptor gene locus. PLoS ONE. 2010;5(11):e13967.
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–94.
Claussnitzer M, Dankel SN, Kyong-Han K, Quon G, Meulemena W, Haugen C, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015. doi:10.1056/NEJMoa1502214.
Li S, Zhao JH, Luan J, Langenberg C, Luben RN, Shaw KT, et al. Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia. 2011;54(4):776–82.
Choquet H, Meyre D. Genetics of obesity: what have we learned? Curr Genomics. 2011;12:169–79.
Ahmad T, Lee IM, Pare G, Chasman DI, Rose L, Ridker PM, Mora S. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011;34(3):675–80.
Li S, Zhao JH, Luan J, Ekelund U, Luben RN, Khaw KT, et al. Physical activity attenuates the genetic predisposition to obesity in 20,000 men and women from EPIC-Norfolk prospective population study. PLoS Med. 2010;7(8):e1000332.
Paneni F, Costantino S, Cosentino F. Role of oxidative stress in endothelial insulin resistance. World J Diabetes. 2015;6(2):326–32.
Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;103:2653–8.
Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Ann Rev Genet. 2012;46:265–87.
Cheng Z, Almeida FA. Mitochondrial alternation in type 2 diabetes and obesity. Cell Cycle. 2014;13(6):890–7.
Toledo FG, Goodpaster BH. The role of weight loss and exercise in correcting skeletal muscle mitochondrial abnormalities in obesity, diabetes and aging. Mol Cell Endocrinol. 2013;379:30–4.
Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia. Diabetes Care. 2008;31(2):S262–8.
Sleigh A, Raymond-Barker P, Thackray K, Porter D, Hatunic M, Vottero A, Burren C, Mitchell C, McIntyre M, Brage S, et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest. 2011;121:2457–61.
Zheng LD, Linarelli LE, Longhua L, Wall SS, Greenawald MH, Seidel RW, et al. Insulin resistance is associated with epigenetic and genetic regulation of mitochondrial DNA in obese humans. Clin Epigentics. 2015. doi:10.1186/s13148-015-0093-1.
Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez Gianotti T, Castano GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010;52:1992–2000.
Barres R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, O’Gorman DF, Zierath JR. Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab. 2012;15:405–11.
Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191–200.
Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2014;11(2):463–82.
Pedersen DJ, Guilherme A, Danai LV, Heyda L, Matevossian A, Cohen J, et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab. 2015;4:507–18.
Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Prately R, Zinman B. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007;30(3):753–9.
Zhang Y, Hu G, Zhang L, Mayo R, Chen L. A novel testing model for opportunistic screening of pre-diabetes and diabetes among U.S. adults. PLoS ONE. 2015. doi:10.137/journal.pone.0120382.
Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Lancet. 2012;379(9833):2279–90.
DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26(1):61–9.
Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabetes. 2015;6(2):296–303.
Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin–sensitive prediabetic subjects. Circulation. 2000;101:975–80.
Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.
Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214–22.
Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB, Wilson BW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219–25.
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–24.
Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care. 2005;28(6):1526–7.
Uranga-Ocio JA, Bastus-Diez S, Delkader-Palacios D, Garcia-Cristobal N, Leal-Garcia A, Abalo-Delgado R. Enteric neuropathy associated to diabetes mellitus. Rev Esp Enferm Dig. 2015;107(6):366–73.
Smith D, Williams C, Ferris C. Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. Gastroenterol Clin N Am. 2003;32:619–58.
Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–90.
Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–60.
Lambadiari V, Triantafyllou K, Dimitriadis GD. Insulin action in muscle and adipose tissue in type 2 diabetes: the significance of blood flow. World J Diabetes. 2015;6(4):626–33.
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.
American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2014;38(1):S8–16.
Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012;16(1):7–12.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.
Thorpe AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015. doi:10.1155/2015/241583.
Rinella ME. Nonalcoholic fatty liver disease a systematic review. JAMA. 2015;313(22):2263–73.
Zhang XQ, Xu DF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1768–76.
Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non alcoholic fatty liver disease. Clin Biochem. 2015. doi:10.1016/j.clinbiochem.2015.06.023.
Buchholz EM, Rathmore SS, Reid KJ, Jones PG, Chan PS, Rich MW, et al. Body mass index and mortality in acute myocardial infarction patients. Am J Med. 2012;125:796–803.
Mullen JT, Moorman DW, Davenport DL. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg. 2009;250:166–72.
Migaj J, Prokop E, Straburzynska-Migaj E, Lesiak M, Grajek S, Mitkowski P. Does influence of obesity on prognosis differ in men and women? A study of obesity paradox in patients with acute coronary syndrome. Kardiol Pol. 2015. doi:10.5603/KP.a2015.0087.
Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol. 2015. doi:10.1016/j.annepidem.2015.02.008.
Costanzo P, Cleland JGF, Pellicori P, Clark AL, Hepburn D, Kilpatirck ES, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Int Med. 2015;162(9):610–8.
Jerant A, Bertakis KD, Franks P. Body mass index and health care utilization in diabetic and nondiabetic individuals. Med Care. 2015. doi:10.1097/MLR.343.
Kortelainen MI, Porvari K. Extreme obesity and associated cardiovascular disease verified at autopsy: time trends over 3 decades. Am J Forensic Med Pathol. 2011;32:372–7.
Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010;33:1097–102.
Graziani F, Biasucci LM, Cialdella P, Lizzo G, Giubilato S, Della Bono R, et al. Thromboxane production in morbidly obese subjects. Am J Cardiol. 2011;107:1656–61.
Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTierman C. J Am Coll Cardiol. 2000;35(3):537–44.
Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87:507–20.
Stone NJ, Robinson JG, Lichtenstien AH, Goff DC, Lloyd-Jones DM, Smith SC, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–43.
Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors. Institute of medicine. Clinical guidelines we can trust. Washington, DC: National Academies Press; 2011.
Xu W, Shubina M, Goldberg SI, Turchin A. Body mass index and all-cause mortality in patients with hypertension. Obesity. 2015. doi:10.1002/oby.21129.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.
Bueter M, Ahmed A, Ashrafian H, le Roux CW. Surg Obes Relat Dis. 2009;5(5):615–20.
Tanida M, Yamamoto N, Shibamoto T, Rahmouni K. Involvement of hypothalamic AMP-activated protein kinase in leptin-induces sympathetic nerve activation. PLoS ONE. 2013;8(2):e56660.
Greenfield JR. Melanocortin signaling and the regulation of blood pressure in human obesity. J Neuroendocrinol. 2011;23(2):186–93.
Carmichael CY, Wainford RD. Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep. 2015;17:39–47.
Hall JE, do Carmo JM, da Silva AA, Wang Z, et al. Obesity-induces hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.
Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87:497–9.
Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666–78.
Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, Jan van Geuns R, et al. The influence of optimal medical treatment on the “obesity paradox”, body mass index and long-term mortality in patients treated with percutaneous coronary interventions: a prospective cohort study. BMJ Open. 2012;2:e000535.
Luna-Luna M, Medina-Urrutia A, Vargas-Alarcon G, Coss-Rovirosa F, Vargas-Barron J, Perez-Mendez O. Adipose tissue in metabolic syndrome: onset and progression of atherosclerosis. Arch Med Res. 2015. doi:10.1016/j.arcmed.2015.05.007.
Di Chiara T, Argano C, Scaglione A, Corrao S, Pinto A, Scaglione R. Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk. Acta Cardiol. 2015;70(1):33–40.
Berg AH, Scherer PE. Adipose tissue, inflammation and cardiovascular disease. Circ Res. 2005;96:939–49.
Wu X, Zhu B, Fu L, Wang H, Zhou B, Zou S, Shi J. Prevalence, incidence, and mortality of stroke in the Chinese island populations: a systematic review. PLoS ONE. 2013;8:e78629.
Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21:1693–9.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10.
Hajhosseiny R, Matthews GK, Lip GY. The metabolic syndrome, atrial fibrillation and stroke: tackling an emerging epidemic. Heart Rhythm. 2015. doi:10.1016/j.hrthm.2015.06.038.
Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxford). 2010;72:32–7.
Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, Vasan RS, Benjamin EJ. JAMA. 2004;292(20):2471–7.
Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2015. doi:10.1161/Circulationaha.1007.702795.
Hardy CM, Birse RT, Wolf MJ, Yu L, Bodmer R, Gibbs AG. Obesity-associated cardiac dysfunction in starvation-selectee drosophila melanogaster. Am J Physiol Regul Integr Comp Physiol. 2015. doi:10.1152/ajpregu.00160.2015.
Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, Malik R. Diabetic cardiomyopathy—a distinct disease? Best Pract Res Clin Endocrinol Metab. 2009;23(3):347–60.
Waddingham MT, Edgley AJ, Tsuchimochi H, Kelly DJ, Shirai M, Pearson JT. Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J Diabetes. 2015;6(7):943–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Blackstone, R.P. (2016). Obesity-Related Diseases and Syndromes: Insulin Resistance, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Cardiovascular Disease, and Metabolic Syndrome. In: Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-39409-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-39409-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-39407-7
Online ISBN: 978-3-319-39409-1
eBook Packages: MedicineMedicine (R0)